JPH1180009A - Agent for improving brain function and agent for preventing lowering of brain function - Google Patents
Agent for improving brain function and agent for preventing lowering of brain functionInfo
- Publication number
- JPH1180009A JPH1180009A JP9267813A JP26781397A JPH1180009A JP H1180009 A JPH1180009 A JP H1180009A JP 9267813 A JP9267813 A JP 9267813A JP 26781397 A JP26781397 A JP 26781397A JP H1180009 A JPH1180009 A JP H1180009A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- agent
- vitamin
- brain function
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003925 brain function Effects 0.000 title claims description 12
- 239000000284 extract Substances 0.000 claims abstract description 17
- 244000124209 Crocus sativus Species 0.000 claims abstract description 11
- 235000015655 Crocus sativus Nutrition 0.000 claims abstract description 11
- 235000013974 saffron Nutrition 0.000 claims abstract description 10
- 239000004248 saffron Substances 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 9
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 6
- 239000011720 vitamin B Substances 0.000 claims abstract description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 10
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 7
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 6
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 5
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 5
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 5
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 5
- 235000002532 grape seed extract Nutrition 0.000 claims description 5
- 229940087603 grape seed extract Drugs 0.000 claims description 5
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 5
- 230000006870 function Effects 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 21
- 239000003814 drug Substances 0.000 abstract description 13
- 235000008100 Ginkgo biloba Nutrition 0.000 abstract description 6
- 229930003935 flavonoid Natural products 0.000 abstract description 6
- 150000002215 flavonoids Chemical class 0.000 abstract description 6
- 235000017173 flavonoids Nutrition 0.000 abstract description 6
- 238000007391 self-medication Methods 0.000 abstract description 6
- 235000011201 Ginkgo Nutrition 0.000 abstract description 5
- 241000218628 Ginkgo Species 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract description 2
- 230000001490 effect on brain Effects 0.000 abstract description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract description 2
- 239000011726 vitamin B6 Substances 0.000 abstract description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 210000002969 egg yolk Anatomy 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019158 vitamin B6 Nutrition 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- 208000013677 cerebrovascular dementia Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000001209 crocus sativus l. Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、脳機能の改善剤お
よび低下予防剤に関する。更に詳しくは、副作用のない
脳機能の改善剤および低下予防剤に関する。TECHNICAL FIELD [0001] The present invention relates to an agent for improving brain function and an agent for preventing its decline. More specifically, the present invention relates to an agent for improving brain function and a preventive agent for lowering brain function without side effects.
【0002】[0002]
【従来の技術】近年、我が国の平均寿命は着実に伸び続
け、超高齢化社会の到来が間近に迫っている。これに伴
ない、加齢と共に増加する老年期痴呆症、いわゆるボケ
は、単に医学的な問題にとどまらず、社会的にも深刻な
問題となってきている。2. Description of the Related Art In recent years, the average life expectancy of Japan has been steadily increasing, and a super-aging society is imminent. Along with this, senile dementia, which is increasing with aging, so-called blurring, is not only a medical problem but also a serious social problem.
【0003】ボケに関する研究は、世界中で盛んに行わ
れているが、その原因となる疾患は多岐にわたり、症状
も多種多様である。そして、アルツハイマー病を始めと
する多くの痴呆症は、未だその原因や明確な治療法が殆
んど解決されていない。また、臨床の場においては、一
度梗塞などによって生じた器質病変に対する効果的な治
療はかなり困難であり、一旦侵された見当識、記銘力等
の知的機能の回復も極めて困難である。従って、ボケ、
痴呆症に対しては、早い段階で再発防止や治療を開始す
ること、そして常に予防に努めることが重要となる。[0003] Research on blurring has been actively conducted all over the world, but the disease causing the disease is diverse, and the symptoms are also diverse. Many causes of dementia such as Alzheimer's disease have yet to be solved for their causes or clear treatment methods. Further, in a clinical setting, it is extremely difficult to effectively treat an organic lesion once caused by an infarction or the like, and it is also extremely difficult to restore intellectual functions such as orientation, memorization and the like once affected. Therefore, blur,
For dementia, it is important to prevent recurrence and start treatment at an early stage, and to always strive to prevent it.
【0004】老年者の場合の痴呆的疾患の大部分は、脳
血管性痴呆とアルツハイマー型痴呆、あるいはこれら両
者の混合型である。これらに対する慢性期の治療薬とし
ては、脳循環改善薬あるいは脳代謝賦活薬が使用される
が、実際的な効果は証明されていない。特に、合成薬物
などの場合、長期間投与によるタキフィラキシーや様々
な副作用を避けることができないのが実情である。[0004] Most of the dementia diseases in the elderly are cerebrovascular dementia and Alzheimer-type dementia, or a mixture of both. Chronic cerebral circulation improvers or cerebral metabolic activators are used as therapeutic agents for these chronic phases, but their practical effects have not been proven. In particular, in the case of a synthetic drug or the like, the fact is that tachyphylaxis and various side effects due to long-term administration cannot be avoided.
【0005】このような観点から、最近では薬用の植物
や天然由来のもので、ボケの防止や改善効果を有するも
のが注目され、探索研究されている。これらのものは、
副作用が殆んどないので、特にセルフメディケーション
への応用において、重要な位置を占めているものと考え
られる。また、臨床における治療は、高度な臨床検査や
診察をもとに、専門の医師により治療方針が決められ、
治療が行われている。しかるに、専門の外来を持つ病院
が少ないことや、通院などの時間や手間を惜んで、大げ
さにこのような外来を訪れることをためらい、病状を進
行させてしまうことが多い。[0005] From such a viewpoint, recently, a medicinal plant or a plant of natural origin, which has an effect of preventing or improving blurring, attracts attention and is being searched for and researched. These things are
Since there are few side effects, it is considered to have an important position especially in self-medication applications. In addition, the treatment in the clinic is determined by a specialist doctor based on advanced clinical tests and consultations,
Treatment is taking place. However, there are few hospitals that have specialized outpatient departments, and many patients often hesitate to visit such outpatient departments and spare their time and effort in going to the hospital to progress their illness.
【0006】従って、このような点からみても、手軽な
セルフメディケーションによる対応は重要である。セル
フメディケーションの場合、自分自身の自覚症状や薬剤
師のアドバイスなどによって薬剤を選択することによる
ので、それに用いられる薬剤には、十分なる安全性とよ
り広い総合的な効果が求められることになる。[0006] Therefore, even in view of the above, it is important to take measures by simple self-medication. In the case of self-medication, drugs are selected based on their own subjective symptoms and the advice of a pharmacist, so that the drugs used for them are required to have sufficient safety and a wider comprehensive effect.
【0007】現在市場には、脳や神経の働きを改善また
は維持するとされているものは数多くあり、その効果も
立証されつつあるが、それぞれ脳神経や脳機能に対する
作用の仕方はまちまちである。また、脳の構造や働きは
非常に複雑かつ繊細で、微妙な生体内のバランス(恒常
性)の上に成り立っている。従って、一部の薬剤や健康
食品の多量または継続的な摂取による偏った作用は、か
えって生体のバランスを崩し、脳の活動や機能維持に悪
影響を与える可能性がある。[0007] At present, there are many products on the market that are thought to improve or maintain the functions of the brain and nerves, and their effects are being proved. However, the methods of acting on brain nerves and brain functions are various. In addition, the structure and function of the brain are extremely complex and delicate, and are based on subtle balance (homeostasis) in the living body. Therefore, a biased action due to a large amount or continuous intake of some drugs and health foods may disturb the balance of the living body and adversely affect the activity and function of the brain.
【0008】[0008]
【発明が解決しようとする課題】本発明の目的は、副作
用などの点で殆んど心配がなく、特にセルフメディケー
ションへの応用において、脳の機能に対して効果的かつ
より広い総合的な効果を有する脳機能の改善剤および低
下予防剤を提供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide almost no concern about side effects and the like, and particularly to the application to self-medication, to have an effective and broader overall effect on brain functions. An object of the present invention is to provide an agent for improving brain function and a preventive agent for lowering the effect.
【0009】[0009]
【課題を解決するための手段】かかる本発明の目的は、
サフランの粉末またはエキス、銀杏葉エキス、卵黄レシ
チン、ビタミンB群を有効成分とする脳機能の改善剤お
よび低下予防剤によって達成される。SUMMARY OF THE INVENTION The object of the present invention is as follows.
It is achieved by an agent for improving and preventing brain function comprising saffron powder or extract, ginkgo biloba extract, egg yolk lecithin and vitamin B group as active ingredients.
【0010】[0010]
【発明の実施の形態】サフラン(Crocus sativus L.)
は、古来中国の伝統医学において、生理痛、月経不順等
の婦人病に用いられた生薬である。サフランは、記憶学
習能力の低下予防作用やアルコールによる海馬長期増強
の抑制を改善する作用を有し(特開平7-69908号公報)、
脳の記憶中枢を直接刺激することが分っている。本発明
においては、サフランの乾燥雌しべの粉末またはこれか
ら水、アルコール、その他の有機溶媒あるいはこれらの
混合溶媒を用い、室温条件下または加熱条件下で抽出し
たエキスが用いられる。DETAILED DESCRIPTION OF THE INVENTION Saffron (Crocus sativus L.)
Is a crude drug that has been used in traditional Chinese medicine for women's diseases such as menstrual cramps and menstrual irregularities. Saffron has an effect of improving the suppression of memory learning ability decline and suppression of hippocampal long-term potentiation by alcohol (Japanese Patent Laid-Open No. 7-69908),
It has been shown to directly stimulate the memory centers of the brain. In the present invention, a powder of a dried pistil of saffron or an extract extracted therefrom using water, alcohol, another organic solvent or a mixed solvent thereof under a room temperature condition or a heating condition is used.
【0011】銀杏葉エキスには、脳の血液循環を改善す
る作用のあることが知られており、西欧では、老年者の
ボケ防止用あるいは血液循環改善用に既に使用されてい
る。銀杏葉エキスには、20種類以上のフラボノイドが多
く含まれており、その中のギンコライド、ビロバライド
というフラボノイドには、活性酸素や血小板活性化因子
の抑制、脳の血流障害や心臓病などに対する様々な薬理
効果や機能が期待される。本発明においては、銀杏葉か
ら水、アルコール、その他の有機溶媒あるいはこれらの
混合溶媒を用い、室温条件下または加熱条件下で抽出し
たエキスあるいは溶媒処理等を行って、有効成分である
フラボノイドの濃度を一定濃度に迄精製したものが用い
られる。Ginkgo biloba extract is known to have a function of improving blood circulation in the brain, and has already been used in Western Europe for preventing blurring of the elderly or improving blood circulation. Ginkgo biloba extract contains a lot of more than 20 types of flavonoids, among which flavonoids such as ginkgolide and bilobalide are used to suppress active oxygen and platelet activating factor, and to prevent various diseases such as cerebral blood flow disorder and heart disease. A great pharmacological effect and function are expected. In the present invention, water, alcohol, other organic solvent or a mixed solvent thereof from ginkgo biloba is subjected to extraction or solvent treatment or the like extracted at room temperature or under heating conditions, and the concentration of the flavonoid as an active ingredient. Purified to a certain concentration is used.
【0012】卵黄レシチンには、ホスファチジルコリン
という物質が多量に含まれている。このホスファチジル
コリンは、人間の細胞の膜成分として欠かせないもので
あり、また神経伝達物質であるアセチルコリンの原料で
もある。アルツハイマー型老人性痴呆症の原因は、この
アセチルコリンの激減にあるとみられており、卵黄レシ
チンを摂取することは、それの予防につながることが期
待される。[0012] Egg yolk lecithin contains a large amount of a substance called phosphatidylcholine. This phosphatidylcholine is indispensable as a membrane component of human cells and is also a raw material of acetylcholine, a neurotransmitter. The cause of Alzheimer's senile dementia is thought to be due to the drastic decrease of acetylcholine, and ingestion of egg yolk lecithin is expected to lead to its prevention.
【0013】また、ビタミンB群は、神経のビタミンと
呼ばれている。特に、ビタミンB6やビタミンB12には、
神経細胞を修復する働きや生存を維持する働きのあるこ
とが報告されており、その他神経伝達物質の合成促進作
用も報告されており、脳の働きを良くする効果が期待さ
れている。[0013] The vitamin B group is called a nerve vitamin. In particular, vitamin B 6 and vitamin B 12
It has been reported that it has a function of repairing nerve cells and a function of maintaining survival, and it has also been reported that it has an effect of promoting the synthesis of neurotransmitters, and is expected to have an effect of improving the function of the brain.
【0014】以上の4成分に加えて、ドコサヘキサエン
酸、ぶどう種子エキス、骨髄エキスおよびビタミンEの
少くとも一種を更に配合することも有効である。In addition to the above four components, it is also effective to further add at least one of docosahexaenoic acid, grape seed extract, bone marrow extract and vitamin E.
【0015】ドコサヘキサエン酸(DHA)は、かつおやま
ぐろ等の魚の脂に多く含まれているω-3系高度不飽和脂
肪酸であり、DHAを含む魚を多く食べている子供の知能
指数が高い理由はそこにあるとして、最近注目を集めた
健脳成分であって、アルツハイマー型痴呆症や脳血管性
痴呆症に対する臨床試験でもその効果が確認されてい
る。Docosahexaenoic acid (DHA) is a highly unsaturated ω-3 fatty acid contained in fats of fish such as bonito and tuna, and the reason why children who eat a lot of fish containing DHA have a high intelligence index. Is a healthy brain component that has recently attracted attention, and its effects have been confirmed in clinical trials for Alzheimer-type dementia and cerebrovascular dementia.
【0016】ぶどう種子エキスは、プロアントシアニジ
ンというフラボノイドを多く含み、強い抗酸化作用のあ
ることが報告されている。そして、それの抗酸化力は、
ビタミンC、ビタミンE、β-カロチン等よりも強いこと
が報告されている。本発明においては、ぶどう種子か
ら、水、アルコール、その他の有機溶媒あるいはこれら
の混合溶媒を用い、室温条件下または加熱条件下で抽出
したエキスあるいは溶媒処理等を行って、有効成分であ
るフラボノイドの濃度を一定濃度に迄精製したものが用
いられる。It has been reported that grape seed extract contains a large amount of flavonoids called proanthocyanidins and has strong antioxidant activity. And its antioxidant power is
It is reported that it is stronger than vitamin C, vitamin E, β-carotene, etc. In the present invention, from grape seeds, using water, alcohol, other organic solvent or a mixed solvent thereof, extract or solvent treatment or the like extracted under room temperature conditions or under heating conditions, the flavonoid of the active ingredient Purified to a certain concentration is used.
【0017】骨髄エキスは、脳の細胞膜成分であるリン
脂質を多量に含んでいる。脳神経の新陳代謝は活発に行
われるため、その原料となり得る成分を摂取することは
脳の活動を活発にする。その他、ミネラルやビタミンを
豊富に含んでいるので、健康にも良い。本発明において
は、哺乳類の骨より骨髄部分を機械的に押出したものあ
るいはそれから水、アルコール、その他の有機溶媒ある
いはこれらの混合溶媒を用い、室温条件下または加熱条
件下で抽出したエキスが用いられる。The bone marrow extract contains a large amount of phospholipid, which is a cell membrane component of the brain. Since the metabolism of the cranial nerves is actively performed, ingesting a component that can be the raw material activates the brain. In addition, it is good for health because it is rich in minerals and vitamins. In the present invention, a bone marrow part mechanically extruded from mammalian bone or an extract extracted therefrom using water, alcohol, another organic solvent or a mixed solvent thereof at room temperature or under heating is used. .
【0018】更に、ビタミンEにも、ぶどう種子エキス
と同様の作用のあることが分っている。活性酸素は、動
脈硬化や老化現象と深いつながりがあるとされており、
これを抑制することは脳血管障害の予防に効果のあるこ
とが予想される。Furthermore, it has been found that vitamin E has the same action as grape seed extract. Active oxygen is said to have a deep connection with arteriosclerosis and aging phenomenon,
It is expected that suppressing this will be effective in preventing cerebrovascular disorders.
【0019】また、ドコサヘキサエン酸、骨髄エキス、
ビタミンEには、他の脂溶性のビタミンや成分を良く溶
かし、その吸収効率を高める働きがある。Docosahexaenoic acid, bone marrow extract,
Vitamin E has the function of dissolving other fat-soluble vitamins and components well and increasing its absorption efficiency.
【0020】以上の各成分は、それぞれ異なる作用機序
によって直接または間接的に脳の機能改善作用や機能低
下予防作用が期待されている。代表的な作用としては、
直接脳や神経細胞に作用し、その働きを活発にする作
用、脳内や脳に到達する血流を改善する作用、脳全体ま
たは脳神経細胞の代謝を賦活する作用、脳神経細胞や血
管を傷害する因子を除く作用および神経細胞の生存を維
持する作用などが考えられ、従って脳の機能を全体的に
改善もしくは低下予防するには、それぞれサフラン粉末
またはエキス、銀杏葉エキス、卵黄レシチンおよびビタ
ミンB群(特にビタミンB6)を組合せて用いる必要があ
る。Each of the above components is expected to directly or indirectly have a function of improving brain function or a function of preventing function decline by a different mechanism of action. Typical effects are:
Acts directly on the brain and nerve cells to activate them, improves blood flow in the brain and reaching the brain, activates the metabolism of the whole brain or brain nerve cells, damages brain nerve cells and blood vessels It is thought to have the effect of removing factors and maintaining the survival of nerve cells. Therefore, to improve or prevent brain function overall, saffron powder or extract, ginkgo extract, egg yolk lecithin and vitamin B group, respectively (Especially vitamin B 6 ) must be used in combination.
【0021】これらは、医薬品または食品の形で提供さ
れる。医薬品として用いる場合には、散剤、顆粒、錠
剤、糖衣錠、カプセル剤、液剤等の形で提供され、また
食品として用いる場合には、ガム、キャンディー、ゼリ
ー、錠菓、飲料等の形で提供される。These are provided in the form of pharmaceuticals or foods. When used as pharmaceuticals, they are provided in the form of powders, granules, tablets, dragees, capsules, liquids, etc., and when used as foods, they are provided in the form of gums, candies, jellies, tablet confections, beverages, etc. You.
【0022】投与量または配合量は、対象となる患者の
年齢、性別、体重、症状あるいは改善剤として使用する
か予防剤として使用するかなどを考慮して適宜決められ
るが、一般には成人1日当り、サフランの粉末で約3〜30
0mg、またエキスで約0.3〜30mg、銀杏葉エキスで約5〜5
00mg、卵黄レシチンで約5〜500mg、ビタミンB群で約0.5
〜50mgである。更に、他の成分が配合される場合には、
ドコサヘキサエン酸が約20〜2000mg、ぶどう種子エキス
が約3〜300mg、骨髄エキスが約20〜2000mg、ビタミンE
が約20〜2000mg服用される。The dose or compounding amount is appropriately determined in consideration of the age, sex, body weight, symptom of the target patient or whether it is used as an improving agent or a prophylactic agent. About 3-30 with saffron powder
0mg, about 0.3-30mg in extract, about 5-5 in ginkgo extract
00mg, about 5-500mg with egg yolk lecithin, about 0.5 with vitamin B group
5050 mg. Furthermore, when other components are blended,
Docosahexaenoic acid about 20-2000mg, grape seed extract about 3-300mg, bone marrow extract about 20-2000mg, vitamin E
Is taken about 20-2000 mg.
【0023】[臨床試験例]サフラン雌しべ粉末10重量
%、銀杏葉エキス5重量%、卵黄レシチン1重量%、ビタミ
ンB6 0.15重量%、ビタミンE 15重量%および増量剤(しそ
油、密ロウ)68.85重量%よりなり、1粒当りの内容量を20
0mgとしたゼラチン皮膜ソフトカプセル6粒(1日当り)
を、推奨摂取量とした。 (対象患者)健康診断では異常が認められない健常者で、
極く軽度のボケの自覚症状を訴えた人を選定 (用法、用量、投与期間)上記ソフトカプセルを1日3回、
1回2カプセルを毎食後、3ケ月間投与 (経過観察と効果判定)専門の医師による問診と表1のよ
うな質問表を作成し、その回答を点数化して評価 表1 質問表 (点数) 3.よくある 2.たまにある 1.ほとんどない 0.全くない 質問内容 回答点数 1) 不安を感じる (不安) 2) 焦ったり、いらいらする (焦燥感) 3) わけもなく沈んだ気分になる (抑鬱) 4) 喜びや悲しみをうまく表現できない (感情面) 5) 人と会ったり話すのが億劫(おっくう)になった (対人接触障害) 6) ちょっとしたことで怒ったり泣いたりする (不穏・興奮) 7) 夜、知らないうちに出歩いていることがある (夜間徘徊) 8) 些細なことでうろたえたり、疑い深くなる (せん妄) 9) 幻覚を見ることがある (幻覚) 10)物事を悪い方に考えてしまう (妄想) 11)よく眠れない (睡眠障害) 12)寝付きが悪い (睡眠障害) 13)これまで出来た簡単な計算が困難になった (計算力障害) 14)頭痛や頭が思い感じがする (自覚症状) 15)めまいがする (自覚症状) 16)しびれ感がする (自覚症状) 17)言葉に詰まる(言葉が出てこない) (日常生活機能評価) 18)耳が聞こえ難くなった (日常生活機能評価) 19)視力の衰えを感じる (日常生活機能評価) 20)根気がなく、物事に集中できない (日常生活機能評価) 21)急用なのに体が動かないまたは動くのがつらい (日常生活機能評価) 22)落ちつきがなくじっとしていられない (日常生活機能評価) 23)箸で食べるとボロボロこぼす (日常生活機能評価) 24)電話の相手の名前が思い出せない (記憶力障害) 25)親しい人の名前を思い出せないことがある (記憶力障害) 26)最近起きた出来事や大事な約束事を忘れてしまう (記憶力障害) 27)昔の友人や恩師の名前が思い出せない (記憶力障害) 28)自分が何処にいるのか分からなくなるときがある (見当識障害) 29)お酒を飲むとすぐに酔っぱらってしまう (アルコール障害) 30)悪酔いする (アルコール障害)31)飲んだときの記憶がなくなる (アルコール障害) 点数合計 回答点数の合計が10以上減少した場合を「有効」、5〜9減
少下場合を「やや有効」として評価[Clinical test example] Saffron pistil powder 10 weight
%, Ginkgo biloba extract 5% by weight, egg yolk lecithin 1% by weight, vitamin
B60.15% by weight, vitamin E 15% by weight and bulking agent (shiso
(Oil, dense wax) 68.85% by weight, the content per grain is 20
6 capsules of gelatin-coated soft capsules with 0 mg (per day)
Was the recommended intake. (Target patients) Healthy subjects who have no abnormalities in the health examination,
Select a person who complained of extremely mild blurring (dose, dosage, administration period)
Administer 2 capsules once every meal for 3 months (follow-up observation and efficacy evaluation)
Create a questionnaire and evaluate the answers by scoring them. Contents of question Answer score 1) feel anxiety (anxiety) 2) get irritated or irritated (feeling sensation) 3) feel uncomfortablely depressed (depression) 4) can't express joy and sadness well (emotional side) 5) meet people 6) I get angry or cry with a small incident (disturbance / excitation) 7) I sometimes go out without knowing at night (wandering at night) 8 ) Become panicking or suspicious by trivial things (delirium) 9) I sometimes see hallucinations (hallucinations) 10) Think about things badly (delusions) 11) I can't sleep well (sleep disorders) 12) I fall asleep (Sleep disorder) 13) Difficulty performing simple calculations (calculation impairment) 14) Headache or headache (subjective symptoms) 15) Dizziness (subjective symptoms) 16) Numbness (Subjective symptoms) 17) Stuck in words (Words do not come out) (Evaluation of daily life function) 18) Difficulty hearing (Evaluation of daily life functions) 19) Feel impaired vision (Evaluation of daily life functions) 20) Insatiable and unable to concentrate on things (Evaluation of daily life functions) 21) The body does not move or it is difficult to move even if it is urgent (daily life) (Life function evaluation) 22) Restless and unable to stay still (Everyday function evaluation) 23) Eating with chopsticks spills (Everyday function evaluation) 24) I can't remember the name of the other party to call (Memory impairment) 25) Sometimes you can't remember the name of a close person (memory impairment) 26) You forget recent events and important promises (memory impairment) 27) You can't remember the names of old friends and teachers (memory impairment) 28) Sometimes I don't know where I am (orientation disorder) 29) I get drunk immediately after drinking (alcohol disorder) 30) I get drunk (alcohol disorder)31) I lose my memory when I drink (Alcohol disorder) Total points If the total number of answer points decreases by 10 or more, "valid", 5-9 reduction
Evaluate a little lower as "Slightly effective"
【0024】(症例) 症例1:42才の男性で、通常生活において支障をきたす程
ではないが、数年前に比べてもの忘れが激しくなった。
特に、ちょっとした約束や予定などを完全に忘れてしま
うことがしばしばある。また、人名や地名など、よく知
っている筈の物事を思い出せないことがある。(Case) Case 1: A 42-year-old man who did not hinder his normal life, but he forgot more than a few years ago.
In particular, they often forget completely about a few promises or appointments. Also, you may not be able to remember things you know well, such as names of people or places.
【0025】投与前と投与3ケ月後の結果は、後記表2の
如くであり、回答点数の合計が52点から44点へと8点減
少し、やや有効と評価した。主として、日常生活機能が
改善された。The results before administration and three months after administration are shown in Table 2 below. The total number of response points decreased from 52 points to 44 points by 8 points, and was evaluated as somewhat effective. Mainly, daily life functions were improved.
【0026】症例2:55才の男性で、取引先の担当者の名
前を何度も忘れたり、以前にはなかったが、話しをして
いて言葉に詰まり、うまく説明できないことがある。Case 2: A 55-year-old man who has forgotten the name of the person in charge of a business partner many times, or who has never been there before, has spoken and is stuck in words, and cannot explain well.
【0027】投与前と投与3ケ月後の結果は、後記表2の
如くであり、回答点数の合計が46点から37点へと9点減
少し、やや有効と評価した。主として、睡眠障害と日常
生活機能が改善された。The results before administration and 3 months after administration are shown in Table 2 below. The total number of response points decreased from 46 points to 37 points by 9 points, and was evaluated as somewhat effective. Mainly, sleep disorders and daily living functions were improved.
【0028】症例3:37才の男性で、良く飲酒するが最近
酔い易く、少し飲み過ぎると記憶がなくなることが多
い。また、寝付きが悪く、なかなか疲れがとれない。Case 3: A 37-year-old man who drinks well but is easily sick recently and often loses his memory after drinking too much. In addition, they have difficulty falling asleep and are not easily tired.
【0029】投与前と投与3ケ月後の結果は、下記表2の
如くであり、回答点数の合計が36点から21点へと15点減
少し、有効と評価した。主として、アルコールによる記
憶障害、睡眠障害、日常生活機能が改善された。 表2 自覚症状等の改善効果 症例1 症例2 症例3 質問No. 試験前 3ケ月後 試験前 3ケ月後 試験前 3ケ月後 1) 0 0 0 0 0 0 2) 1 1 1 1 2 1 3) 0 0 1 1 2 1 4) 1 1 0 0 0 0 5) 2 2 0 0 0 0 6) 1 1 2 2 0 0 7) 0 0 0 0 0 0 8) 0 0 1 1 0 0 9) 0 0 0 0 0 0 10) 1 1 0 0 0 0 11) 1 1 3 1 2 1 12) 1 1 3 1 3 1 13) 2 2 2 2 2 2 14) 2 2 3 2 3 2 15) 3 2 1 1 0 0 16) 2 2 2 2 0 0 17) 3 2 3 2 1 1 18) 2 2 2 2 1 1 19) 2 2 3 3 0 0 20) 3 2 3 2 2 1 21) 2 2 1 1 0 0 22) 2 1 1 1 1 1 23) 2 1 1 1 1 1 24) 3 2 3 2 2 1 25) 3 3 2 2 2 1 26) 2 2 3 2 2 1 27) 3 3 2 2 1 1 28) 0 0 0 0 0 0 29) 3 2 1 1 3 2 30) 2 2 1 1 3 1 31) 3 2 1 1 3 1 合計 52 44 46 37 36 21The results before and 3 months after administration are shown in Table 2 below.
As a result, the total number of answers decreased by 15 points from 36 points to 21 points
A little, evaluated as effective. Mainly by alcohol
Memory disorders, sleep disorders and daily living functions improved. Table 2 Improvement effects of subjective symptomsCase 1 Case 2 Case 3 Question No. Before the test 3 months later Before the test 3 months later Before the test 3 months later 1) 0 0 0 0 0 0 2) 1 1 1 1 2 1 3) 0 0 1 1 2 1 4) 1 1 0 0 0 0 5) 2 2 0 0 0 0 6) 1 1 2 2 0 0 7) 0 0 0 0 0 0 8) 0 0 1 1 0 0 9) 0 0 0 0 0 0 10) 1 1 0 0 0 0 11) 1 1 3 1 2 1 12) 1 1 3 1 3 1 13) 2 2 2 2 2 2 14) 2 2 3 2 3 2 15) 3 2 1 1 0 0 16) 2 2 2 2 0 0 17) 3 2 3 2 1 1 18) 2 2 2 2 1 1 19) 2 2 3 3 0 0 20) 3 2 3 2 2 1 21) 2 2 1 1 0 0 22) 2 1 1 1 1 1 23) 2 1 1 1 1 1 24) 3 2 3 2 2 1 25) 3 3 2 2 2 1 26) 2 2 3 2 2 1 27) 3 3 2 2 1 1 28) 0 0 0 0 0 0 29) 3 2 1 1 3 2 30) 2 2 1 1 3 131) 3 2 1 1 3 1 Total 52 44 46 37 36 21
【0030】[0030]
【発明の効果】本発明に係る脳機能の改善剤および低下
予防剤は、副作用などの点で殆んど心配がなく、特にセ
ルフメディケーションへの応用において、十分なる安全
性とより広い総合的な効果が発揮される。EFFECT OF THE INVENTION The agent for improving and preventing cerebral function according to the present invention has almost no concern about side effects and the like, and has sufficient safety and broader comprehensiveness especially in application to self-medication. Effect is exhibited.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 31/44 A61K 31/44 31/455 31/455 31/51 31/51 31/525 31/525 31/68 31/68 31/685 31/685 35/28 35/28 35/54 35/54 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 31/44 A61K 31/44 31/455 31/455 31/51 31/51 31/525 31/525 31/68 31/68 31/685 31/685 35/28 35/28 35/54 35/54
Claims (2)
キス、卵黄レシチン、ビタミンB群を有効成分とする脳
機能の改善剤および低下予防剤。1. An agent for improving and preventing brain function comprising saffron powder or extract, ginkgo biloba extract, egg yolk lecithin, and vitamin B group as active ingredients.
ス、骨髄エキスおよびビタミンEの少くとも一種が更に
配合された請求項1記載の脳機能の改善剤および低下予
防剤。2. The agent for improving and preventing brain function according to claim 1, further comprising at least one of docosahexaenoic acid, grape seed extract, bone marrow extract and vitamin E.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9267813A JPH1180009A (en) | 1997-09-12 | 1997-09-12 | Agent for improving brain function and agent for preventing lowering of brain function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9267813A JPH1180009A (en) | 1997-09-12 | 1997-09-12 | Agent for improving brain function and agent for preventing lowering of brain function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH1180009A true JPH1180009A (en) | 1999-03-23 |
Family
ID=17449971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9267813A Withdrawn JPH1180009A (en) | 1997-09-12 | 1997-09-12 | Agent for improving brain function and agent for preventing lowering of brain function |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH1180009A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000297039A (en) * | 1999-04-09 | 2000-10-24 | Yakult Honsha Co Ltd | Dream promoter |
| WO2001076580A1 (en) * | 2000-04-11 | 2001-10-18 | Takara Bio Inc. | Remedies |
| KR20020069539A (en) * | 2001-02-26 | 2002-09-05 | 주식회사 두산 | Composition for healthy brain |
| JP2003300891A (en) * | 2002-04-10 | 2003-10-21 | Taiyo Kagaku Co Ltd | Cerebral function ameliorating composition |
| JP2004537577A (en) * | 2001-08-09 | 2004-12-16 | デグッサ フード イングレディエンツ ゲーエムベーハー | (Rhizo) phosphatidylserine-containing preparation for prevention and treatment of stress state in warm-blooded animals |
| JP2005041812A (en) * | 2003-07-22 | 2005-02-17 | Noevir Co Ltd | Cell activator |
| JP2009269834A (en) * | 2008-05-01 | 2009-11-19 | Dhc Co | Bone resorption inhibitor, food and drink for bone resorption inhibition and quasi drug |
| JP2018030795A (en) * | 2016-08-23 | 2018-03-01 | 株式会社Hbcフナト | Brain function-improving composition |
-
1997
- 1997-09-12 JP JP9267813A patent/JPH1180009A/en not_active Withdrawn
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000297039A (en) * | 1999-04-09 | 2000-10-24 | Yakult Honsha Co Ltd | Dream promoter |
| WO2001076580A1 (en) * | 2000-04-11 | 2001-10-18 | Takara Bio Inc. | Remedies |
| KR20020069539A (en) * | 2001-02-26 | 2002-09-05 | 주식회사 두산 | Composition for healthy brain |
| JP2004537577A (en) * | 2001-08-09 | 2004-12-16 | デグッサ フード イングレディエンツ ゲーエムベーハー | (Rhizo) phosphatidylserine-containing preparation for prevention and treatment of stress state in warm-blooded animals |
| JP2003300891A (en) * | 2002-04-10 | 2003-10-21 | Taiyo Kagaku Co Ltd | Cerebral function ameliorating composition |
| JP2005041812A (en) * | 2003-07-22 | 2005-02-17 | Noevir Co Ltd | Cell activator |
| JP2009269834A (en) * | 2008-05-01 | 2009-11-19 | Dhc Co | Bone resorption inhibitor, food and drink for bone resorption inhibition and quasi drug |
| JP2018030795A (en) * | 2016-08-23 | 2018-03-01 | 株式会社Hbcフナト | Brain function-improving composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Halsted | Dietary supplements and functional foods: 2 sides of a coin? | |
| TWI583390B (en) | Ellagitannins rich extracts composition | |
| Balch et al. | Prescription for Natural Cures: A Self-Care Guide for Treating Health Problems with Natural Remedies Including Diet, Nutrition, Supplements, and Other Holistic Methods | |
| Hoffer et al. | Orthomolecular medicine for everyone: Megavitamin therapeutics for families and physicians | |
| JP2024051173A (en) | Maintenance Agent | |
| RU2368385C2 (en) | Ginkgo complexes used for strengthening cognitive functions and decreasing mental fatigue | |
| JPH1180009A (en) | Agent for improving brain function and agent for preventing lowering of brain function | |
| Murray | 5-HTP: The natural way to overcome depression, obesity, and insomnia | |
| JP2020188755A (en) | Food composition for improving brain function, brain function improver, food composition for enhancing brain-derived neurotrophic factor, food composition for suppressing stress hormone excretion, enhancer of brain-derived neurotrophic factor and stress hormone excretion suppressor | |
| Torkos | The Canadian encyclopedia of natural medicine | |
| Bowden | The Most Effective Natural Cures on Earth: The Surprising, Unbiased Truth about what Treatments Work and why | |
| Ningsih et al. | Effect of fortification of massage oil for breastfeeding mothers on physical, chemical and organoleptic tests of Jitu Oil | |
| Bodkin | Alternative therapies for the holistic care of the HIV/AIDS patient: overview | |
| Bongiorno | Complementary and alternative medical treatment for depression | |
| Fife | Virgin Coconut Oil: Nature's Miracle Medicine | |
| Stengler | The Natural Physician's Healing Therapies: Proven Remedies Medical Doctors Don't Know | |
| JP2006176421A (en) | Composition for ameliorating brain function and/or blood fluidity, containing allium sativum and egg yolk | |
| Panse | Nutritional Psychiatry as Basis of Nutraceutical Development for Mental Illness in Aging Population | |
| Cook | Pain Erasers: The Complete Natural Medicine Guide to Safe, Drug-Free Relief | |
| Kurn et al. | Herbs and Nutrients for Neurologic Disorders: Treatment Strategies for Alzheimer's, Parkinson's, Stroke, Multiple Sclerosis, Migraine, and Seizures | |
| Murray | Arthritis: Your Natural Guide to Healing With Diet, Vitamins, Minerals, Herbs, Exercise, and Other Natural Methods | |
| Ayurveda | Anti-aging effect of amalaki rasayana in healthy elderly | |
| Courteney | 500 Most Important Health Tips: An A–Z of alternative health hints to help over 250 conditions | |
| Rowland | The Nutritional Bypass | |
| Martin | Surviving AIDS and Cancer: A Guide to Staying Healthy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20050415 |